Rice Hall James & Associates LLC Decreases Stock Holdings in Medpace Holdings, Inc. $MEDP

Rice Hall James & Associates LLC lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,409 shares of the company’s stock after selling 11,045 shares during the period. Medpace makes up about 2.6% of Rice Hall James & Associates LLC’s portfolio, making the stock its 4th largest holding. Rice Hall James & Associates LLC owned approximately 0.33% of Medpace worth $46,999,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Precision Wealth Strategies LLC bought a new stake in Medpace during the third quarter worth $784,000. CWM LLC lifted its position in shares of Medpace by 311.4% during the 3rd quarter. CWM LLC now owns 28,496 shares of the company’s stock worth $14,652,000 after buying an additional 21,569 shares during the last quarter. Pacer Advisors Inc. boosted its stake in Medpace by 159.4% in the third quarter. Pacer Advisors Inc. now owns 111,290 shares of the company’s stock valued at $57,221,000 after buying an additional 68,384 shares in the last quarter. Norden Group LLC boosted its stake in Medpace by 10.0% in the third quarter. Norden Group LLC now owns 1,234 shares of the company’s stock valued at $634,000 after buying an additional 112 shares in the last quarter. Finally, Parcion Private Wealth LLC acquired a new position in Medpace during the 3rd quarter worth approximately $392,000. 77.98% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 21,503 shares of the firm’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 387,925 shares of company stock worth $233,386,647. Insiders own 20.30% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $567.56 on Friday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $626.26. The business’s 50-day moving average is $579.62 and its 200-day moving average is $480.17. The company has a market capitalization of $15.99 billion, a price-to-earnings ratio of 39.69, a P/E/G ratio of 2.16 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the firm earned $3.01 earnings per share. Medpace’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. BMO Capital Markets assumed coverage on Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. Jefferies Financial Group raised their price objective on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Robert W. Baird set a $613.00 target price on shares of Medpace in a report on Friday, October 24th. Finally, Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $490.82.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.